Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
8 - I was curious, to your knowledge , how many companies are currently operating within the PAAB meeting report exemption , either legitimately or otherwise . I know if anybody has this information it would be likely yourself. I am curious and was hoping you could shed some light on this issue
-
There is no meeting report exemption. The PAAB did away with that supplementary guideline on April 1. PAAB Code section 1.5 was rewritten and it allows an exemption from review for reports that are not advertising by the PAAB definition in Code s1.8 i.e. it is unbiased information not about the sponsor's products. Anything with some emphasis on the sponsor's products distributed to a broad audience in an unsolicited manner is "advertising" by the Food & Drugs Act definition of advertising and the PAAB Code definition. The content and relation to the sponsor are the key elements, not who the publisher is. Thus, if a company commissions a report about a study related to their product, it is most probably "advertising".
